Breast Cancer Research and Treatment

, Volume 114, Issue 1, pp 71–83 | Cite as

Mammary tumor development from T47-D human breast cancer cells in obese ovariectomized mice with and without estradiol supplements

  • Katai J. Nkhata
  • Amitabha Ray
  • Soner Dogan
  • Joseph P. Grande
  • Margot P. Cleary
Preclinical Study

Abstract

Obesity is a risk factor for postmenopausal breast cancer, particularly for development of estrogen-receptor (ER)-positive tumors. Additionally, obesity is implicated in breast cancer progression. However, few studies address mechanisms of action of how obesity mediates these responses. Our goal was to address how obesity and/or elevated serum leptin affects tumor formation from ER-positive T47-D cells. In Study 1 ovariectomized CD-1 nude female mice were injected with goldthioglucose (GTG) at 0.5 mg/g body weight in saline or the vehicle at 6 weeks of age. At 10 weeks of age mice were inoculated with T47-D cells and implanted with estrogen pellets. In Study 2 mice were injected with 0.3 mg/g GTG or the vehicle. At 10 weeks of age cells were inoculated and mice were implanted with estrogen or placebo pellets. Mice were followed until 30 weeks of age. Some GTG mice became obese and others were non-responders. In Study 1 no mice developed tumors. In Study 2 mice with placebo pellets developed more tumors than mice with estrogen pellets, 50% vs. 13%. GTG-obese mice with placebo pellets had a 100% tumor incidence compared to 50% and 20% for GTG-lean and controls without estrogen. Serum leptin was higher in obese compared to lean mice and adiponectin was not affected by body weight. Adiponectin:leptin ratio was significantly reduced in obese compared to lean mice. Leptin, leptin receptor and signaling protein expression were determined in mammary and tumor tissue. Leptin and STAT3 were most abundant in tumors. These findings suggest that in vivo estrogen suppressed proliferation of T47-D cells but without supplemental estrogen obesity enhanced tumor development. The exact reason for this is not presently clear.

Keywords

T47-D cells Breast cancer Obesity Gold thioglucose Leptin Adiponectin Xenograft CD-1 mice 

References

  1. 1.
    Tehard B, Lahmann PH, Riboli E et al (2004) Anthropometry, breast cancer and menopausal status: use of repeated measurements over 10 years of follow-up-results of the French E3N women’s cohort study. Int J Cancer 111:264–269PubMedCrossRefGoogle Scholar
  2. 2.
    Sweeney C, Blair CK, Anderson KE et al (2004) Risk factors for breast cancer in elderly women. Am J Epidemiol 160:868–875PubMedCrossRefGoogle Scholar
  3. 3.
    Cleary MP, Maihle NJ (1997) The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med 216:28–43PubMedGoogle Scholar
  4. 4.
    Staszewski J (1977) Breast cancer and body build. Prev Med 6:410–415PubMedCrossRefGoogle Scholar
  5. 5.
    Adami HO, Rimsten A, Stenkvist B et al (1977) Influence of height, weight and obesity on risk of breast cancer in an unselected Swedish population. Br J Cancer 36:787–792PubMedGoogle Scholar
  6. 6.
    Toti A, Agugiaro S, Amadori D et al (1986) Breast cancer risk factors in Italian women: a multicentric case-control study. Tumori 72:241–249PubMedGoogle Scholar
  7. 7.
    Velie EM, Nechuta S, Osuch JR (2005) Lifetime reproductive and anthropometric risk factors for breast cancer in postmenopausal women. Breast Dis 24:17–35PubMedGoogle Scholar
  8. 8.
    Harvie M, Howell A, Vierkant RA et al (2005) Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev 14:656–661PubMedCrossRefGoogle Scholar
  9. 9.
    Lahmann PH, Hoffmann K, Allen N et al (2004) Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 111:762–771PubMedCrossRefGoogle Scholar
  10. 10.
    Zhu K, Caulfield J, Hunter S et al (2005) Body mass index and breast cancer risk in African American women. Ann Epidemiol 15:123–128PubMedCrossRefGoogle Scholar
  11. 11.
    Mehta RR, Hart G, Das Gupta TK (1992) Steroid receptors in breast cancer patients. Influence of obesity and age at diagnosis. Anticancer Res 12:1311–1314PubMedGoogle Scholar
  12. 12.
    Nomura Y, Tashiro H, Hamada Y et al (1984) Relationship between estrogen receptors and risk factors of breast cancer in Japanese pre- and postmenopausal patients. Breast Cancer Res Treat 4:37–43PubMedCrossRefGoogle Scholar
  13. 13.
    Carmichael AR (2006) Obesity and prognosis of breast cancer. Obes Rev 7:333–340PubMedCrossRefGoogle Scholar
  14. 14.
    Vona-Davis L, Howard-McNatt M, Rose DP (2007) Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 8:395–408PubMedCrossRefGoogle Scholar
  15. 15.
    Greenberg JA, Boozer CN (1999) The leptin-fat ratio is constant, and leptin may be part of two feedback mechanisms for maintaining the body fat set point in non-obese male Fischer 344 rats. Horm Metab Res 31:525–532PubMedCrossRefGoogle Scholar
  16. 16.
    Shimizu H, Shimomura Y, Hayashi R et al (1997) Serum leptin concentration is associated with total body fat mass, but not abdominal fat distribution. Int J Obes Relat Metab Disord 21:536–541PubMedCrossRefGoogle Scholar
  17. 17.
    Havel PJ, Kasim-Karakas S, Mueller W et al (1996) Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 81:4406–4413PubMedCrossRefGoogle Scholar
  18. 18.
    Ostlund RE, Jr., Yang JW, Klein S et al (1996) Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. J Clin Endocrinol Metab 81:3909–3913PubMedCrossRefGoogle Scholar
  19. 19.
    Hu X, Juneja SC, Maihle NJ et al (2002) Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 94:1704–1711PubMedGoogle Scholar
  20. 20.
    Laud K, Gourdou I, Pessemesse L et al (2002) Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line. Mol Cell Endocrinol 188:219–226PubMedCrossRefGoogle Scholar
  21. 21.
    Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V et al (2002) Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun 293:622–628PubMedCrossRefGoogle Scholar
  22. 22.
    Yin N, Wang D, Zhang H et al (2004) Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res 64:5870–5875PubMedCrossRefGoogle Scholar
  23. 23.
    Chen C, Chang YC, Liu CL et al (2006) Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1. Breast Cancer Res Treat 98:121–132PubMedCrossRefGoogle Scholar
  24. 24.
    Ray A, Nkhata KJ, Cleary MP (2007) Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol 30:1499–1509PubMedGoogle Scholar
  25. 25.
    Frankenberry KA, Skinner H, Somasundar P et al (2006) Leptin receptor expression and cell signaling in breast cancer. Int J Oncol 28:985–993PubMedGoogle Scholar
  26. 26.
    Cleary MP, Hu X, Grossmann ME et al (2007) Prevention of mammary tumorigenesis by intermittent caloric restriction: does caloric intake during refeeding modulate the response? Exp Biol Med (Maywood) 232:70–80Google Scholar
  27. 27.
    Ishikawa M, Kitayama J, Nagawa H (2004) Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 10:4325–4331PubMedCrossRefGoogle Scholar
  28. 28.
    Garofalo C, Koda M, Cascio S et al (2006) Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res 12:1447–1453PubMedCrossRefGoogle Scholar
  29. 29.
    Nakayama S, Miyoshi Y, Ishihara H et al Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis. Breast Cancer Res Treat [Epub PMID: 18163210]Google Scholar
  30. 30.
    Arditi JD, Venihaki M, Karalis KP et al (2007) Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res 39:9–13PubMedCrossRefGoogle Scholar
  31. 31.
    Cleary MP, Phillips FC, Getzin SC et al (2003) Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat 77:205–215PubMedCrossRefGoogle Scholar
  32. 32.
    Cleary MP, Juneja SC, Phillips FC et al (2004) Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors. Exp Biol Med (Maywood) 229:182–193Google Scholar
  33. 33.
    Halter SA, Dempsey P, Matsui Y et al (1992) Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations. Am J Pathol 140:1131–1146PubMedGoogle Scholar
  34. 34.
    Cleary MP, Grande JP, Maihle NJ (2004) Effect of high fat diet on body weight and mammary tumor latency in MMTV-TGF-alpha mice. Int J Obes Relat Metab Disord 28:956–962PubMedCrossRefGoogle Scholar
  35. 35.
    Cleary MP, Grande JP, Juneja SC et al (2004) Diet-induced obesity and mammary tumor development in MMTV-neu female mice. Nutr Cancer 50:174–180PubMedCrossRefGoogle Scholar
  36. 36.
    Ray A, Nkhata KJ, Grande JP et al (2007) Diet-induced obesity and mammary tumor development in relation to estrogen receptor status. Cancer Lett 253:291–300PubMedCrossRefGoogle Scholar
  37. 37.
    Bergen HT, Mizuno TM, Taylor J et al (1998) Hyperphagia and weight gain after gold-thioglucose: relation to hypothalamic neuropeptide Y and proopiomelanocortin. Endocrinology 139:4483–4488PubMedCrossRefGoogle Scholar
  38. 38.
    Waxler SH, Brecher G (1950) Obesity and food requirements in albino mice following administration of goldthioglucose. Am J Physiol 162:428–433PubMedGoogle Scholar
  39. 39.
    Walker CG, Bryson JM, Phuyal JL et al (2002) Dietary modulation of circulating leptin levels: site-specific changes in fat deposition and ob mRNA expression. Horm Metab Res 34:176–181PubMedCrossRefGoogle Scholar
  40. 40.
    Jansen GR (1999) Effect of delta22-5beta-taurocholenic acid on hepatic cholesterol and fatty acid in gold thioglucose obese mice fed low- or high-fat diets. J Nutr Biochem 10:638–643PubMedCrossRefGoogle Scholar
  41. 41.
    Roberts JL, Whittington FM, Enser M (1988) Effects of litter size and subsequent gold-thioglucose-induced obesity on adipose tissue weight, distribution and cellularity in male and female mice: an age study. Br J Nutr 59:519–533PubMedCrossRefGoogle Scholar
  42. 42.
    Morris JS, Carter NP, Ferguson-Smith MA et al (1997) Cytogenetic analysis of three breast carcinoma cell lines using reverse chromosome painting. Genes Chromosomes Cancer 20:120–139PubMedCrossRefGoogle Scholar
  43. 43.
    Kytola S, Rummukainen J, Nordgren A et al (2000) Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer 28:308–317PubMedCrossRefGoogle Scholar
  44. 44.
    Oliveira AM, Ross JS, Fletcher JA (2005) Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Path 124:S16–28PubMedGoogle Scholar
  45. 45.
    Casey G, Lo-Hsueh M, Lopez ME et al (1991) Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 6:1791–1797PubMedGoogle Scholar
  46. 46.
    Liang Y, Wu J, Stancel GM et al (2005) p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. J Steroid Biochem Mol Biol 93:173–182PubMedCrossRefGoogle Scholar
  47. 47.
    Bryson JM, Wensley VR, Phuyal JL et al (1999) Chronic administration of BRL 26830A for 9 weeks improves insulin sensitivity but does not prevent weight gain in gold-thioglucose obese mice. Horm Metab Res 31:317–322PubMedCrossRefGoogle Scholar
  48. 48.
    Johnson PR, Hirsch J (1972) Cellularity of adipose depots in six strains of genetically obese mice. J Lipid Res 13:2–11PubMedGoogle Scholar
  49. 49.
    Siegmund B, Lear-Kaul KC, Faggioni R et al (2002) Leptin deficiency, not obesity, protects mice from Con A-induced hepatitis. Eur J Immunol 32:552–560PubMedCrossRefGoogle Scholar
  50. 50.
    Toth MJ, Poehlman ET, Matthews DE et al (2001) Effects of estradiol and progesterone on body composition, protein synthesis, and lipoprotein lipase in rats. Am J Physiol Endocrinol Metab 280:E496–E501PubMedGoogle Scholar
  51. 51.
    D’Eon TM, Souza SC, Aronovitz M et al (2005) Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J Biol Chem 280:35983–35991PubMedCrossRefGoogle Scholar
  52. 52.
    Keydar I, Chen L, Karby S et al (1979) Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 15:659–670PubMedGoogle Scholar
  53. 53.
    Lacroix M, Leclercq G (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83:249–289PubMedCrossRefGoogle Scholar
  54. 54.
    Chen NY, Holle L, Li W et al (2002) In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R. Int J Oncol 20:813–818PubMedGoogle Scholar
  55. 55.
    Leung CK, Shiu RP (1981) Required presence of both estrogen and pituitary factors for the growth of human breast cancer cells in athymic nude mice. Cancer Res 41:546–551PubMedGoogle Scholar
  56. 56.
    Schafer JM, Lee ES, O’Regan RM et al (2000) Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. Clin Cancer Res 6:4373–4380PubMedGoogle Scholar
  57. 57.
    Chisamore MJ, Ahmed Y, Bentrem DJ et al (2001) Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res 7:3156–3165PubMedGoogle Scholar
  58. 58.
    Tonetti DA, Chisamore MJ, Grdina W et al (2000) Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer 83:782–791PubMedCrossRefGoogle Scholar
  59. 59.
    Parente JE, Walsh MP, Girard PR et al (1989) Effects of gold coordination complexes on neutrophil function are mediated via inhibition of protein kinase C. Mol Pharmacol 35:26–33PubMedGoogle Scholar
  60. 60.
    Hashimoto K, Whitehurst CE, Matsubara T et al (1992) Immunomodulatory effects of therapeutic gold compounds. Gold sodium thiomalate inhibits the activity of T cell protein kinase C. J Clin Invest 89:1839–1848PubMedCrossRefGoogle Scholar
  61. 61.
    Burmester GR (2001) Molecular mechanisms of action of gold in treatment of rheumatoid arthritis—an update. Z Rheumatol 60:167–173PubMedCrossRefGoogle Scholar
  62. 62.
    Meldrum DR, Meng X, Sheridan BC et al (1998) Tissue-specific protein kinase C isoforms differentially mediate macrophage TNFalpha and IL-1beta production. Shock 9:256–260PubMedCrossRefGoogle Scholar
  63. 63.
    St-Denis A, Chano F, Tremblay P et al (1998) Protein kinase C-alpha modulates lipopolysaccharide-induced functions in a murine macrophage cell line. J Biol Chem 273:32787–32792PubMedCrossRefGoogle Scholar
  64. 64.
    Rivadeneira DE, Grobmyer SR, Naama HA et al (2001) Malnutrition-induced macrophage apoptosis. Surgery 129:617–625PubMedCrossRefGoogle Scholar
  65. 65.
    Hide I (2003) Mechanism of production and release of tumor necrosis factor implicated in inflammatory diseases. Nippon Yakurigaku Zasshi 121:163–173PubMedGoogle Scholar
  66. 66.
    Nadra I, Mason JC, Philippidis P et al (2005) Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification? Circ Res 96:1248–1256PubMedCrossRefGoogle Scholar
  67. 67.
    Arnott CH, Scott KA, Moore RJ et al (2002) Tumor necrosis factor-alpha mediates tumor promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene 21:4728–4738PubMedCrossRefGoogle Scholar
  68. 68.
    Pandey M, Loskutoff DJ, Samad F (2005) Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes. FASEB J 19:1317–1319PubMedGoogle Scholar
  69. 69.
    Jee SH, Kim HJ, Lee J (2005) Obesity, insulin resistance and cancer risk. Yonsei Med J 46:449–455PubMedCrossRefGoogle Scholar
  70. 70.
    Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772–783PubMedCrossRefGoogle Scholar
  71. 71.
    de Luca C, Olefsky JM (2008) Inflammation and insulin resistance. FEBS Lett 582:97–105PubMedCrossRefGoogle Scholar
  72. 72.
    Clevenger CV, Furth PA, Hankinson SE et al (2003) The role of prolactin in mammary carcinoma. Endocr Rev 24:1–27PubMedCrossRefGoogle Scholar
  73. 73.
    Ormandy CJ, Hall RE, Manning DL et al (1997) Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab 82:3692–3699PubMedCrossRefGoogle Scholar
  74. 74.
    Favy DA, Rio P, Maurizis JC et al (1999) Prolactin-dependent up-regulation of BRCA1 expression in human breast cancer cell lines. Biochem Biophys Res Commun 258:284–291PubMedCrossRefGoogle Scholar
  75. 75.
    Ramamoorthy P, Sticca R, Wagner TE et al (2001) In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells. Int J Oncol 18:25–32PubMedGoogle Scholar
  76. 76.
    Huang Y, Li X, Jiang J et al (2006) Prolactin modulates phophorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene 25:7565–7576PubMedCrossRefGoogle Scholar
  77. 77.
    Duan R, Ginsburg E, Vonderhaar BK (2008) Estrogen stimulates transcription from the human prolactin distal promoter through AP1 and estrogen responsive elements in T47D human breast cancer cells. Mol Cell Endocrinol 281:9–18PubMedCrossRefGoogle Scholar
  78. 78.
    Utama FE, LeBaron MJ, Neilson LM et al (2006) Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. J Endocrinol 188:589–601PubMedCrossRefGoogle Scholar
  79. 79.
    Williams C, Edvardsson K, Lewandowski SA et al (2008) A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27:1019–1032PubMedCrossRefGoogle Scholar
  80. 80.
    Hartman J, Lindberg K, Morani A et al (2006) Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 66:11207–11213PubMedCrossRefGoogle Scholar
  81. 81.
    Vladusic EA, Hornby AE, Guerra-Vladusic FK et al (2000) Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. Oncol Rep 7:157–167PubMedGoogle Scholar
  82. 82.
    Power KA, Thompson LU (2003) Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation. Breast Cancer Res Treat 81:209–221PubMedCrossRefGoogle Scholar
  83. 83.
    Key T, Appleby P, Barnes I et al (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616PubMedGoogle Scholar
  84. 84.
    Fortunati N, Catalano MG (2006) Sex hormone-binding globulin (SHBG) and estradiol cross-talk in breast cancer cells. Horm Metab Res 38:236–240PubMedCrossRefGoogle Scholar
  85. 85.
    Germain P, Egloff M, Kiefer H et al (1997) Use of confocal microscopy to localize the SHBG interaction with human breast cancer cell lines—a comparison with serum albumin interaction. Cell Mol Biol 43:501–508PubMedGoogle Scholar
  86. 86.
    Murayama Y, Hammond GL, Sugihara K (1999) The shbg gene and hormone dependence of breast cancer: a novel mechanism of hormone dependence of MCF-7 human breast cancer cells based upon SHBG. Breast Cancer 6:338–343PubMedCrossRefGoogle Scholar
  87. 87.
    Hegyi K, Fulop K, Kovacs K et al (2004) Leptin-induced signal transduction pathways. Cell Biol Int 28:159–169PubMedCrossRefGoogle Scholar
  88. 88.
    Garofalo C, Surmacz E (2006) Leptin and cancer. J Cell Physiol 207:12–22PubMedCrossRefGoogle Scholar
  89. 89.
    Fruhbeck G (2006) Intracellular signalling pathways activated by leptin. Biochem J 393:7–20PubMedCrossRefGoogle Scholar
  90. 90.
    Clevenger CV (2004) Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 165:1449–1460PubMedGoogle Scholar
  91. 91.
    Catalano S, Mauro L, Marsico S et al (2004) Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor α in MCF-7 cells. J Biol Chem 279:19908–19915PubMedCrossRefGoogle Scholar
  92. 92.
    Tessitore L, Vizio B, Pesola D et al (2004) adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients. Int J Oncol 24:1529–1535PubMedGoogle Scholar
  93. 93.
    Garofalo C, Sisci D, Surmacz E (2004) Leptin interferes with the effects of the antiestrogen ICI182,780 in MCF-7 breast cancer cells. Clin Cancer Res 10:6466–6475PubMedCrossRefGoogle Scholar
  94. 94.
    Korner A, Wabitsch M, Seidel B et al (2005) Adiponectin expression in humans is dependent on differentiation of adipocytes and down-regulated by humoral serum components of high molecular weight. Biochem Biophys Res Commun 337:540–550PubMedCrossRefGoogle Scholar
  95. 95.
    Dieudonne MN, Bussiere M, Dos Santos E et al (2006) Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 345:271–279PubMedCrossRefGoogle Scholar
  96. 96.
    Wang Y, Lam JB, Lam KS et al (2006) Adiponectin modulates the glycogen synthase kinase-3 beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66:11462–11470PubMedCrossRefGoogle Scholar
  97. 97.
    Grossmann ME, Nkhata KJ, Mizuno NK et al (2008) Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 98:370–379PubMedCrossRefGoogle Scholar
  98. 98.
    Huypens P, Quartier E (2006) Adiponectin expression is paradoxically increased in gold-thioglucose-induced obesity. Horm Metab Res 38:486–490PubMedCrossRefGoogle Scholar
  99. 99.
    Boucher J, Castan-Laurell I, Daviaud D et al (2005) Adipokine expression profile in adipocytes of different mouse models of obesity. Horm Metab Res 37:761–767PubMedCrossRefGoogle Scholar
  100. 100.
    Inoue M, Yano M, Yamakado M et al (2006) Relationship between the adiponectin-leptin ratio and parameters of insulin resistance in subjects without hyperglycemia. Metabolism 55:1248–1254PubMedCrossRefGoogle Scholar
  101. 101.
    Kaaks R (2004) Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp 262:247–260PubMedCrossRefGoogle Scholar
  102. 102.
    Lorincz AM, Sukumar S (2006) Molecular links between obesity and breast cancer. Endocr Relat Cancer 13:279–292PubMedCrossRefGoogle Scholar
  103. 103.
    Hankinson SE, Schernhammer ES (2003) Insulin-like growth factor and breast cancer risk: evidence from observational studies. Breast Dis 17:27–40PubMedGoogle Scholar
  104. 104.
    Lukanova A, Lundin E, Zeleniuch-Jacquotte A et al (2004) Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 150:161–171PubMedCrossRefGoogle Scholar
  105. 105.
    Holmes MD, Pollak MN, Hankinson SE (2002) Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11:862–867PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Katai J. Nkhata
    • 1
  • Amitabha Ray
    • 1
  • Soner Dogan
    • 1
  • Joseph P. Grande
    • 2
  • Margot P. Cleary
    • 1
  1. 1.Hormel InstituteUniversity of MinnesotaAustinUSA
  2. 2.Department of Pathology and Laboratory MedicineMayo ClinicRochesterUSA

Personalised recommendations